Jun 07, 2023 / 04:30PM GMT
Dave Stanton - Jefferies - Analyst
Might make a start. Good afternoon, everyone. My name's Dave Stanton. I'm part of the Jefferies Australia healthcare research team.
It's my great pleasure to introduce Chris Behrenbruch, CEO of Telix, today, who's going to run through a quick presentation. Then, we're going to open it up for questions at the end. So Chris, thanks very much, and over to you.
Chris Behrenbruch - Telix Pharmaceuticals Limited - MD & Group CEO
Yeah. Thanks, David. And I appreciate always the opportunity from the Jefferies team to come and present. Just skipping over the customary disclaimer. So just a bit of introduction about Telix. For those of you who are not familiar with us, and there's a lot of people that are getting up to speed on the story, we're a commercial-stage theranostic radiopharmaceutical company. And we're not a diagnostic imaging company. We're a therapy company that believes in the concept of precision medicine.
We are, as I said, a commercial-stage company doing about USD320 million or so in annualized
Telix Pharmaceuticals Ltd at Jefferies Healthcare Conference Transcript
Feb 15, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers